Trial Profile

Efficacy and Safety of Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy HAIC in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Donafenib (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Sintilimab (Primary)
Indications Liver cancer
Focus Therapeutic Use
Acronyms DoHAICs

24 Oct 2023 Results assessing safety and efficacy of donafenib combined with HAIC and sintilimab in pts with uHCC presented at the 48th European Society for Medical Oncology Congress
06 Jun 2023 Status changed from not yet recruiting to recruiting, as per presented at the 59th Annual Meeting of the American Society of Clinical Oncology
06 Jun 2023 Preliminary Results ( As of February 10, 2023), presented at the 59th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com